Anders Gersel Pedersen
Member of the board since 2010.
Re-elected for the board in 2012 for a one-year term.
Independent.
Dr. Pedersen is executive vice
president of research and development at H. Lundbeck A/S. Before
joining H. Lundbeck A/S in 2000, he worked for Eli Lilly for 11
years, ten of them as a director overseeing worldwide clinical
research in oncology. He is chairman of the board of Genmab A/S and
a member of the board of directors of ALK-Abelló A/S. He is
a member of the European Society of Medical Oncology, the
International Association for the Study of Lung Cancer, the
American Society of Clinical Oncology, the Danish Society of
Medical Oncology and the Danish Society of Internal Medicine. Dr.
Pedersen received his medical degree and a doctoral degree in
neuro-oncology from the University of Copenhagen and a BSc in
business administration from Copenhagen Business School.
Mr. Pedersen is a Danish national, born in 1951.
The special competencies possessed by
Dr. Pedersen that are important for the performance of his duties
in the Company are his scientific qualifications and his extensive
board and management experience from publicly traded, international
pharmaceutical and biotech industries.
